





### AMENDMENTS TO THE CLAIMS

1. (Currently amended) A pharmaceutical composition for treating or preventing an allergic reaction associated with increased IgE levels or for inhibiting NF-κB-mediated cellular proliferation in a mammal, comprising a compound or salt thereof selected from any one of the following formulas:



wherein R is selected from the group consisting of H, C<sub>1</sub>-C<sub>5</sub> alkyl, benzyl, p-fluorobenzyl, and dialkylaminoalkyl, wherein said C<sub>1</sub>-C<sub>5</sub> alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;

wherein R<sub>3</sub>, X, and Y are independently selected from the group consisting of H, halogen, alkoxy, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, OH, OCH<sub>3</sub>, COOH, CN, CF<sub>3</sub>, OCF<sub>3</sub>, NO<sub>2</sub>, COOR'', CHO, and COR'';

wherein R<sub>1</sub> and R<sub>2</sub> are independently selected from the group consisting of H, alkyl, substituted alkyl, C<sub>3</sub>-C<sub>9</sub> cycloalkyl, substituted C<sub>3</sub>-C<sub>9</sub> cycloalkyl, polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heterocyclic, and substituted heterocyclic, wherein said heterocyclic and said substituted heterocyclic contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur, and wherein R<sub>1</sub> and R<sub>2</sub> are not both methyl or phenyl;

wherein substituents of the substituted alkyl, the substituted C<sub>3</sub>-C<sub>9</sub> cycloalkyl, the substituted phenyl, the substituted naphthyl and the substituted heterocyclic are selected from the group consisting of H, halogen, alkoxy, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, OH, OCH<sub>3</sub>, COOH, COOR', COR', CN, CF<sub>3</sub>, OCF<sub>3</sub>, NO<sub>2</sub>, NR'R' and CONR'R';

wherein R' is selected from the group consisting of H, alkyl, substituted alkyl, C<sub>3</sub>-C<sub>9</sub> cycloalkyl, substituted C<sub>3</sub>-C<sub>9</sub> cycloalkyl, polycyclic aliphatic groups, phenyl, ~~substituted phenyl~~, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur; and

wherein R'' is selected from the group consisting of C<sub>1</sub>-C<sub>9</sub> alkyl, wherein said C<sub>1</sub>-C<sub>9</sub> alkyl is selected from the group consisting of straight chain alkyl, branched alkyl, and cyclic alkyl.

2. (Previously presented) The pharmaceutical composition of Claim 1, wherein said polycyclic aliphatic group is selected from the group consisting of adamantyl, bicycloheptyl, camphoryl, bicyclo[2,2,2]octanyl, and norbornyl.

Appl. No. : 10/821,667  
Filed : April 9, 2004

3. (Previously presented) The pharmaceutical composition of Claim 1, wherein said heterocyclic and said substituted heterocyclic is selected from the group consisting of pyridines, thiazoles, isothiazoles, oxazoles, pyrimidines, pyrazines, furans, thiophenes, isoxazoles, pyrroles, pyridazines, 1,2,3-triazines, 1,2,4-triazines, 1,3,5-triazines, pyrazoles, imidazoles, indoles, quinolines, iso-quinolines, benzothiophenes, benzofurans, parathiazines, pyrans, chromenes, pyrrolidines, pyrazolidines, imidazolidines, morpholines, thiomorpholines, and the corresponding saturated heterocyclics.

4. (Currently amended) The pharmaceutical composition of Claim 1, further comprising at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction and/or said cellular proliferation.

5. (Withdrawn- currently amended) A method for treating or preventing an allergic reaction ~~and/or for inhibiting cytokines or leukocytes~~ in a mammal wherein said reaction is caused by an increase in IgE levels comprising administering an IgE-suppressing amount of at least one compound of Claim 1.

6. (Withdrawn) The method of Claim 5 further comprising administering at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction.

7. (Withdrawn) The method of Claim 6, wherein said at least one additional ingredient is selected from the group consisting of a short-acting  $\beta_2$ -adrenergic agonist, a long-acting  $\beta_2$ -adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.

8. (Withdrawn) The method of Claim 6, wherein said at least one additional ingredient is combined with said at least one IgE-suppressing compound in a pharmaceutically acceptable diluent and co-administered to the mammal.

9. (Withdrawn) The method of Claim 8, wherein said at least one IgE-suppressing compound is administered at a dose of about 0.01 mg to about 100 mg per kg body weight per day.

10. (Withdrawn) The method of Claim 9, wherein said dose is administered in divided doses at regular periodic intervals.

**Appl. No.** : 10/821,667  
**Filed** : April 9, 2004

11. (Withdrawn) The method of Claim 10, wherein said regular periodic intervals occur daily.

12. (Withdrawn) A method for treating or preventing asthma in a mammal comprising administering an IgE-suppressing amount of at least one compound of Claim 1.

13. (Withdrawn) The method of Claim 12 further comprising administering at least one additional ingredient which is active in reducing at least one symptom associated with said asthma.

14. (Withdrawn) The method of Claim 13, wherein said additional ingredient is selected from the group consisting of a short-acting  $\beta_2$ -adrenergic agonist, a long-acting  $\beta_2$ -adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.

15. (Withdrawn- currently amended) A method for inhibiting NF- $\kappa$ B-mediated cellular proliferation in a mammal comprising administering an amount of at least one compound of Claim 1.

16. (Withdrawn) The method of Claim 15 further comprising administering at least one additional ingredient which is active in reducing at least one symptom associated with said cellular proliferation.

17. (Withdrawn) The method of Claim 16, wherein said at least one additional ingredient is selected from the group consisting of antifungals, antivirals, antibiotics, anti-inflammatories, and anticancer agents.

18. (Withdrawn) The method of Claim 16, wherein said at least one additional ingredient is selected from the group consisting of alkylating agent, antimetabolite, DNA cutter, topoisomerase I poison, topoisomerase II poison, DNA binder, and spindle poison.

19. (Withdrawn) The method of Claim 16, wherein said at least one additional ingredient is combined with said at least one compound of Claim 1 in a pharmaceutically acceptable diluent and co-administered to the mammal.

20. (Withdrawn) The method of Claim 19, wherein said at least one compound of Claim 1 is administered at a dose of about 0.01 mg to about 100 mg per kg body weight per day.

21. (Withdrawn) The method of Claim 20, wherein said dose is administered in divided doses at regular periodic intervals.


22. (Withdrawn) The method of Claim 21, wherein said regular periodic intervals occur daily.

23. (Withdrawn) The method of Claim 15 further comprising administering at least one other therapy which is effective in ameliorating at least one symptom associated with cellular hyperproliferation.

24. (Withdrawn) The method of Claim 23, wherein said therapy is an anti-cancer therapy.

25. (Withdrawn) The method of Claim 23, wherein said therapy is selected from the group consisting of radiation, immunotherapy, gene therapy, and surgery.


26. (Previously presented) The pharmaceutical composition of Claim 1, wherein  $R_1$  and  $R_2$  are independently selected from the following:



27. (Withdrawn-currently amended) A method of preparing a the compound or salt thereof of Genus 1 of Claim 1, comprising:


converting a Y-substituted-nitro-benzonitrile to a Y-substituted nitro-benzamidine;

reacting the Y-substituted nitro-benzamidine with X-substituted nitro-phenacyl




halide to form a species of the formula **13** ;

reducing the species of the formula **13** to form a species of the formula **14**




; and

acylating the species of the formula **14** to form a species of the formula **15**



28. (Withdrawn-currently amended) A method of preparing a the compound or salt thereof ~~having the formula~~ of Genus 1 of Claim 1, comprising:



~~wherein R is selected from the group consisting of H, C<sub>1</sub>-C<sub>5</sub>-alkyl, benzyl, p-fluorobenzyl, and dialkylaminoalkyl, wherein said C<sub>1</sub>-C<sub>5</sub>-alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;~~

~~wherein R<sub>3</sub>, X, and Y are independently selected from the group consisting of H, halogen, alkoxy, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, OH, OCH<sub>3</sub>, COOH, CN, CF<sub>3</sub>, OCF<sub>3</sub>, NO<sub>2</sub>, COOR'', CHO, and COR'';~~

~~wherein R<sub>1</sub> and R<sub>2</sub> are independently selected from the group consisting of H, alkyl, substituted alkyl, C<sub>3</sub>-C<sub>9</sub> cycloalkyl, substituted C<sub>3</sub>-C<sub>9</sub> cycloalkyl, polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heterocyclic, and substituted heterocyclic, wherein said heterocyclic and said substituted heterocyclic contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;~~

~~wherein said substituents are selected from the group consisting of H, halogen, alkoxy, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, OH, OCH<sub>3</sub>, COOH, COOR', COR', CN, CF<sub>3</sub>, OCF<sub>3</sub>, NO<sub>2</sub>, NR'R', NHCOR' and CONR'R';~~


~~wherein R' is selected from the group consisting of H, alkyl, substituted alkyl, C<sub>3</sub>-C<sub>9</sub> cycloalkyl, substituted C<sub>3</sub>-C<sub>9</sub> cycloalkyl, polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur; and~~

~~wherein R'' is selected from the group consisting of C<sub>4</sub>-C<sub>9</sub> alkyl, wherein said C<sub>4</sub>-C<sub>9</sub> alkyl is selected from the group consisting of straight chain alkyl, branched alkyl, and cyclic alkyl;~~

~~wherein said method comprises steps:~~


~~converting a Y-substituted nitro-benzonitrile to a Y-substituted nitro-benzamidine;~~

~~reacting the Y-substituted nitro-benzamidine with X-substituted acetamido-~~




~~phenacyl halide to form species of the formula 74~~

~~hydrolyzing the species of the formula 74 to form a species of the formula~~




~~acylating the species of the formula 75 to form a species of the formula 76~~



76


; reducing the species of the formula 76 to form a species of the formula 77



77

; and


acylating the species of the formula 77 to form a species of the formula



78

78

29. (Withdrawn-currently amended) A method of preparing a the compound or salt thereof having the formula of Genus 2 of Claim 1, comprising:



Genus 2;

wherein R is selected from the group consisting of H, C<sub>1</sub>-C<sub>5</sub>-alkyl, benzyl, p-fluorobenzyl, and dialkylaminoalkyl, wherein said C<sub>1</sub>-C<sub>5</sub>-alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;

wherein R<sub>3</sub>, X, and Y are independently selected from the group consisting of H, halogen, alkoxy, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, OH, OCH<sub>3</sub>, COOH, CN, CF<sub>3</sub>, OCF<sub>3</sub>, NO<sub>2</sub>, COOR'', CHO, and COR'';

wherein R<sub>1</sub> and R<sub>2</sub> are independently selected from the group consisting of H, alkyl, substituted alkyl, C<sub>3</sub>-C<sub>9</sub> cycloalkyl, substituted C<sub>3</sub>-C<sub>9</sub> cycloalkyl, polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heterocyclic, and substituted heterocyclic, wherein said heterocyclic and said substituted heterocyclic



~~contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;~~

~~wherein said substituents are selected from the group consisting of H, halogen, alkoxy, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, OH, OCH<sub>3</sub>, COOH, COOR', COR', CN, CF<sub>3</sub>, OCF<sub>3</sub>, NO<sub>2</sub>, NR'R', NHCOR' and CONR'R';~~

~~wherein R' is selected from the group consisting of H, alkyl, substituted alkyl, C<sub>3</sub>-C<sub>9</sub> cycloalkyl, substituted C<sub>3</sub>-C<sub>9</sub> cycloalkyl, polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur; and~~

~~wherein R'' is selected from the group consisting of C<sub>1</sub>-C<sub>9</sub> alkyl, wherein said C<sub>1</sub>-C<sub>9</sub> alkyl is selected from the group consisting of straight chain alkyl, branched alkyl, and cyclic alkyl;~~


~~wherein said method comprises the following steps:~~

~~converting a Y-substituted-nitro-benzonitrile to a Y-substituted nitro-benzamidine;~~

~~reacting the Y-substituted nitro-benzamidine with X-substituted cyano-phenacyl~~

~~halide to form a species of the formula 92~~

~~reducing the species of the formula 92 to form a species of the formula 93~~




~~acylating the species of the formula 93 and subsequently performing a hydrolysis~~


~~to form a species of the formula 94~~

~~; and~~

aminating the species of the formula 94 to form a species of the formula 95



30. (Withdrawn-currently amended) A method of preparing a the compound or salt thereof having the formula of Genus 2 of Claim 1, comprising:



~~wherein R is selected from the group consisting of H, C<sub>1</sub>-C<sub>5</sub>-alkyl, benzyl, p-fluorobenzyl, and dialkylaminoalkyl, wherein said C<sub>1</sub>-C<sub>5</sub>-alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;~~

~~wherein R<sub>3</sub>, X, and Y are independently selected from the group consisting of H, halogen, alkoxy, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, OH, OCH<sub>3</sub>, COOH, CN, CF<sub>3</sub>, OCF<sub>3</sub>, NO<sub>2</sub>, COOR'', CHO, and COR'';~~

~~wherein R<sub>1</sub> and R<sub>2</sub> are independently selected from the group consisting of H, alkyl, substituted alkyl, C<sub>3</sub>-C<sub>9</sub> cycloalkyl, substituted C<sub>3</sub>-C<sub>9</sub> cycloalkyl, polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heterocyclic, and substituted heterocyclic, wherein said heterocyclic and said substituted heterocyclic contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;~~

~~wherein said substituents are selected from the group consisting of H, halogen, alkoxy, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, OH, OCH<sub>3</sub>, COOH, COOR', COR', CN, CF<sub>3</sub>, OCF<sub>3</sub>, NO<sub>2</sub>, NR'R', NHCOR' and CONR'R';~~

~~wherein R' is selected from the group consisting of H, alkyl, substituted alkyl, C<sub>3</sub>-C<sub>9</sub> cycloalkyl, substituted C<sub>3</sub>-C<sub>9</sub> cycloalkyl, polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl;~~

Appl. No. : 10/821,667  
Filed : April 9, 2004

~~wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur; and~~


~~wherein R'' is selected from the group consisting of C<sub>1</sub>-C<sub>9</sub> alkyl, wherein said C<sub>1</sub>-C<sub>9</sub> alkyl is selected from the group consisting of straight chain alkyl, branched alkyl, and cyclic alkyl;~~

~~wherein said method comprises the following steps:~~


~~converting a Y-substituted nitro-benzonitrile to a Y-substituted nitro-benzamidine;~~

~~converting methyl X-substituted 4-acetyl benzoate to a methyl X-substituted 4-(alpha-bromoacetyl) benzoate;~~


~~reacting the Y-substituted nitro-benzamidine with methyl X-substituted 4-(alpha-bromoacetyl) benzoate to form species of the formula 103~~




~~hydrolyzing the species of the formula 103 to form a species of the formula 104~~




~~aminating the species of the following formula 104 to form a species of the~~



reducing and amidating the formula 105 to form a species of the formula 106



31. (Withdrawn-currently amended) A method of preparing a the compound or salt thereof having the formula of Genus 3 of Claim 1, comprising:



~~wherein R is selected from the group consisting of H, C<sub>1</sub>-C<sub>5</sub>-alkyl, benzyl, p-fluorobenzyl, and dialkylaminoalkyl, wherein said C<sub>1</sub>-C<sub>5</sub>-alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;~~

~~wherein R<sub>3</sub>, X, and Y are independently selected from the group consisting of H, halogen, alkoxy, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, OH, OCH<sub>3</sub>, COOH, CN, CF<sub>3</sub>, OCF<sub>3</sub>, NO<sub>2</sub>, COOR'', CHO, and COR'';~~

~~wherein R<sub>1</sub> and R<sub>2</sub> are independently selected from the group consisting of H, alkyl, substituted alkyl, C<sub>3</sub>-C<sub>9</sub> cycloalkyl, substituted C<sub>3</sub>-C<sub>9</sub> cycloalkyl, polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heterocyclic, and substituted heterocyclic, wherein said heterocyclic and said substituted heterocyclic contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;~~

~~wherein said substituents are selected from the group consisting of H, halogen, alkoxy, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, OH, OCH<sub>3</sub>, COOH, COOR' COR', CN, CF<sub>3</sub>, OCF<sub>3</sub>, NO<sub>2</sub>, NR'R', NHCOR' and CONR'R';~~

~~wherein R' is selected from the group consisting of H, alkyl, substituted alkyl, C<sub>3</sub>-C<sub>9</sub> cycloalkyl, substituted C<sub>3</sub>-C<sub>9</sub> cycloalkyl, polycyclic aliphatic groups, phenyl,~~

~~substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl,~~  
~~wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein~~  
~~said heteroatom is independently selected from the group consisting of nitrogen, oxygen~~  
~~and sulfur; and~~


~~wherein R'' is selected from the group consisting of C<sub>1</sub>-C<sub>9</sub> alkyl, wherein said C<sub>1</sub>-~~  
~~C<sub>9</sub> alkyl is selected from the group consisting of straight chain alkyl, branched alkyl, and~~  
~~cyclic alkyl;~~

~~wherein said method comprises the following steps:~~


~~converting a Y-substituted-alkoxycarbonyl-benzonitrile to a Y-substituted~~  
~~alkoxycarbonyl-benzamidine;~~

~~reacting the Y-substituted alkoxycarbonyl-benzamidine with X-substituted cyano-~~


~~phenacyl halide to form a species of the formula 142~~




~~hydrolyzing the species of the formula 142 to form a species of the formula 143~~



~~amidating the species of the formula 143 to form a species of the formula 143a~~




~~hydrolyzing the species of the formula 143a to form a species of the formula 143b~~




~~; and~~

amidating the species of the formula 143b to form a species of the formula 144



32. (Withdrawn-currently amended) A method of preparing a the compound or salt thereof having the formula of Genus 4 of Claim 1, comprising:



wherein R is selected from the group consisting of H, C<sub>1</sub>-C<sub>5</sub>-alkyl, benzyl, p-fluorobenzyl, and dialkylaminoalkyl, wherein said C<sub>1</sub>-C<sub>5</sub>-alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;

wherein R<sub>3</sub>, X, and Y are independently selected from the group consisting of H, halogen, alkoxy, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, OH, OCH<sub>3</sub>, COOH, CN, CF<sub>3</sub>, OCF<sub>3</sub>, NO<sub>2</sub>, COOR'', CHO, and COR'';

wherein R<sub>1</sub> and R<sub>2</sub> are independently selected from the group consisting of H, alkyl, substituted alkyl, C<sub>3</sub>-C<sub>9</sub>-cycloalkyl, substituted C<sub>3</sub>-C<sub>9</sub>-cycloalkyl, polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heterocyclic, and substituted heterocyclic, wherein said heterocyclic and said substituted heterocyclic contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;

wherein said substituents are selected from the group consisting of H, halogen, alkoxy, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, OH, OCH<sub>3</sub>, COOH, COOR' COR', CN, CF<sub>3</sub>, OCF<sub>3</sub>, NO<sub>2</sub>, NR'R', NHCOR' and CONR'R';

wherein R' is selected from the group consisting of H, alkyl, substituted alkyl, C<sub>3</sub>-C<sub>9</sub>-cycloalkyl, substituted C<sub>3</sub>-C<sub>9</sub>-cycloalkyl, polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein

said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur; and


wherein R" is selected from the group consisting of C<sub>1</sub>-C<sub>9</sub> alkyl, wherein said C<sub>1</sub>-C<sub>9</sub> alkyl is selected from the group consisting of straight chain alkyl, branched alkyl, and cyclic alkyl;

wherein said method comprises the following steps:


converting a Y-substituted-alkoxycarbonyl-benzonitrile to a Y-substituted alkoxycarbonyl-benzamidine;

reacting the Y-substituted alkoxycarbonyl-benzamidine with X-substituted nitro-


phenacyl halide to form a species of the formula 152



reducing the species of the formula 152 to form a species of the formula 153




acylating the species of the formula 153 to form a species of the formula 154



; and

amidating the species of the formula 154 to form a species of the formula 155



33. (Currently amended) A compound selected from the group consisting of:

N-{4-[5-(4-cycloheptylamino-phenyl)-1H-imidazol-2-yl]-phenyl}-  
 cycloheptylamide,

N-{4-[2-(4-(4-fluorobenzoylamino)-phenyl)-3H-imidazol-4-yl]-phenyl}-4-fluoro-  
 benzamide,

Appl. No. : 10/821,667  
Filed : April 9, 2004

N-{4-[5-(4-cyclohexylamino-phenyl)-1H-imidazol-2-yl]-phenyl}-  
cyclohexylamide,

N-{4-[2-(4-(2,4-dichlorobenzoylamino)-phenyl)-3H-imidazol-4-yl]-phenyl}-2,4-  
dichloro-benzamide,

N-{4-[5-(4-(2-methylcyclohexyl)-amino-phenyl)-1H-imidazol-2-yl]-phenyl}-(2-  
methylcyclohexyl)-amide,

N-(3-(5-(3-(1-Adamantanamido)phenyl)-1H-imidazol-2-yl)phenyl)-1-  
adamantanecarboxamide,

N-(4-(5-(3-(1-Adamantanamido)phenyl)-1H-imidazol-2-yl)phenyl)-1-  
adamantanecarboxamide,

N-{4-[5-(4-(2-methylcyclohexyl)-amino-phenyl)-1H-imidazol-2-yl]-phenyl}-(4-  
methylcyclohexyl)-amide,

N-(4-(5-(4-adamantylamidophenyl)-1H-imidazol-2-yl)phenyl)picolinamide,

N-(4-(5-(4-adamantylamidophenyl)-1H-imidazol-2-yl)phenyl)-4-  
methylcyclohexanecarboxamide,

N-(4-(5-(4-adamantylamidophenyl)-1H-imidazol-2-yl)phenyl)-2-  
methylcyclohexanecarboxamide,

N-(4-(5-(4-adamantylamidophenyl)-1H-imidazol-2-  
yl)phenyl)cycloheptanecarboxamide,

N-(4-(2-(4-adamantylamidophenyl)-1H-imidazol-5-  
yl)phenyl)cyclohexanecarboxamide,

N-(4-(5-(4-(cyclohexanecarboxamido)phenyl)-1H-imidazol-2-  
yl)phenyl)picolinamide,

N-(4-(5-(4-(cyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)-2-  
methylcyclohexylamide,

N-(4-(5-(4-(cyclohexanecarboxamido)phenyl)-1H-imidazol-2-  
yl)phenyl)cycloheptylamide,

4-chloro-N-(4-(5-(4-(cyclohexanecarboxamido)phenyl)-1H-imidazol-2-  
yl)phenyl)benzamide,



**Appl. No.** : **10/821,667**  
**Filed** : **April 9, 2004**

3,4-chloro-N-(4-(5-(4-(cyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)benzamide,

N-(4-(5-(4-(4-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)cycloheptanecarboxamide,

N-(4-(2-(4-adamantylamidophenyl)-1H-imidazol-5-yl)phenyl)-4-methylcyclohexanecarboxamide,

N-(4-(5-(4-(4-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)picolinamide,

N-(4-(5-(4-(4-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)benzamide,

N-(4-(5-(4-(4-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)-4-fluorobenzamide,

N-(4-(5-(4-(4-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)-4-chlorobenzamide,

N-(4-(5-(4-(4-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)-3,4-dichlorobenzamide,

N-(4-(5-(4-(4-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)-4-methoxybenzamide,

N-(4-(5-(4-(4-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)-2,3,4,5,6-pentafluorobenzamide,

N-(4-(2-(4-Adamantylamidophenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,

N-(4-(2-(4-(Cyclohexanecarboxamido)phenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,

N-(4-(2-(4-(2-Methylcyclohexanecarboxamido)phenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,

N-(4-(2-(4-(4-Methylcyclohexanecarboxamido)phenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,

N-(4-(5-(4-(Cycloheptanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)nicotinamide,

Appl. No. : 10/821,667  
Filed : April 9, 2004

N-(4-(2-(4-(Benzamido)phenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,  
N-(4-(2-(4-(2,3,4,5,6-Pentafluorobenzamido)phenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,  
N-(4-(2-(4-(3,4-Dichlorobenzamido)phenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,  
N-(4-(2-(4-(4-Fluorobenzamido)phenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,  
N-(4-(2-(4-(4-Chlorobenzamido)phenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,  
N-(4-(2-(4-(4-Methoxybenzamido)phenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,  
N-(4-(2-(4-(4-Nitrobenzamido)phenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,  
N-(4-(2-(4-(1-Adamantanecarboxamido)phenyl)-1H-imidazol-5-yl)phenyl)nicotinamide,  
N-(4-(2-(4-(Cyclohexanecarboxamido)phenyl)-1H-imidazol-5-yl)phenyl)nicotinamide,  
N-(4-(2-(4-(2-Methylcyclohexanecarboxamido)phenyl)-1H-imidazol-5-yl)phenyl)nicotinamide,  
N-(4-(2-(4-(4-Methylcyclohexanecarboxamido)phenyl)-1H-imidazol-5-yl)phenyl)nicotinamide,  
N-(4-(2-(4-(Nicotinamido)phenyl)-1H-imidazol-5-yl)phenyl)nicotinamide,  
N-(4-(2-(4-(3,4-Dichlorobenzamido)phenyl)-1H-imidazol-5-yl)phenyl)nicotinamide,  
N-(4-(2-(4-(2,3,4,5,6-Pentafluorobenzamido)phenyl)-1H-imidazol-5-yl)phenyl)nicotinamide,  
N-(4-(2-(4-(Cycloheptanecarboxamido)phenyl)-1H-imidazol-5-yl)phenyl)nicotinamide,

Appl. No. : 10/821,667  
Filed : April 9, 2004

2-Methyl-N-(4-(2-(4-(cyclohexanecarboxamido)phenyl)-1H-imidazol-5-yl)phenyl)cyclohexanecarboxamide,  
N-(4-(5-(4-(2-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)nicotinamide,  
2-Methyl-N-(4-(2-(4-(4-methylcyclohexanamido)phenyl)-1H-imidazol-5-yl)phenyl)cyclohexanecarboxamide,  
N-(4-(5-(4-(2-Methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)cycloheptanecarboxamide,  
N-(4-(5-(4-(2-Methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)picolinamide,  
N-(4-(5-(4-(pyridin-2-ylcarbonyl)phenyl)-1H-imidazol-2-yl)phenyl)cycloheptanecarboxamide,  
N-(4-(5-(4-(pyridin-2-ylcarbonyl)phenyl)-1H-imidazol-2-yl)phenyl)cyclohexanecarboxamide,  
N-(4-(5-(4-(cycloheptylcarbonyl)phenyl)-1H-imidazol-2-yl)phenyl)benzenamide,  
N-(4-(5-(4-(cycloheptylcarbonyl)phenyl)-1H-imidazol-2-yl)phenyl)picolinamide,  
N-(4-(5-(4-(cycloheptylcarbonyl)phenyl)-1H-imidazol-2-yl)phenyl)cycloheptanecarboxamide,  
4-(2-(4-(4-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-5-yl)-N-cycloheptylbenzamide,  
4-(2-(4-(2-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-5-yl)-N-cycloheptylbenzamide,  
4-(2-(4-(adamantylamidophenyl)-1H-imidazol-5-yl)-N-cycloheptylbenzamide,  
Adamantane-1-carboxylic acid (4-{5-[4-(adamantan-2-ylcarbonyl)-phenyl]-1H-imidazol-2-yl}-phenyl)-amide,  
N-Adamantan-2-yl-4-[2-[4-(cyclohexanecarbonyl-amino)-phenyl]-3H-imidazol-4-yl]-benzamide,

Appl. No. : 10/821,667  
Filed : April 9, 2004

Cycloheptane carboxylic acid (4-{5-[4-(adamantan-2-ylcarbamoyl)-phenyl]-1H-imidazol-2-yl}-phenyl)-amide,

Pyridine-2-carboxylic acid (4-{5-[4-(adamantan-2-ylcarbamoyl)-phenyl]-1H-imidazol-2-yl}-phenyl)-amide,

N-(4-(5-(4-(Cyclohexylcarbamoyl)phenyl)-1H-imidazol-2-yl)phenyl)picolinamide,

N-(4-(2-(4-(Cyclohexanecarboxamido)phenyl)-1H-imidazol-5-yl)-N-cyclohexylbenzamide, and

N-(4-(5-(4-(Cyclohexylcarbamoyl)phenyl)-1H-imidazol-2-yl)phenyl)cycloheptanecarboxamide.